Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease.
复制标题
DOI：
10.3389/fonc.2020.580141
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
Schvartsman G
中科院分区：
文献类型：
--
作者：
Di Villeneuve L;Souza IL;Tolentino FDS;Ferrarotto R;Schvartsman G
唾液腺癌 (SGC) 占头颈部恶性肿瘤的比例不到 5%，可进一步细分为 20 多种组织学亚型。在大多数情况下，晚期疾病的治疗以形态学为指导。 SGC 一般对标准化疗反应较差，持续时间短且毒性显着。最近，新一代测序为每种 SGC 亚型的分子特征提供了重要的信息，不仅改善了形态相似的肿瘤类型之间的诊断区分，而且还确定了决定肿瘤生物学并可能适合靶向治疗的新驱动途径。最常见的组织学亚型是腺样囊性癌，它通常含有染色体易位，导致 MYB-NFIB 癌基因，并具有不同程度的 Myb 表达。在较小的亚群中，出现 NOTCH1 突变，从而导致更具侵袭性的疾病以及对 Notch 抑制剂的潜在敏感性。唾液管癌可能过度表达 Her-2 和雄激素受体，在接受批准用于其他适应症的靶向治疗后，具有良好的临床结果。分泌性癌以前称为乳腺类似分泌性癌，其特征在于 ETV6-NTRK3 融合，这既有助于将其与形态相似的腺泡细胞癌区分开来，又使其对 Trk 抑制剂敏感。在本文中，我们讨论了分子异常、它们对肿瘤生物学的影响以及最常见 SGC 亚型的治疗机会，并回顾了已发表和正在进行的临床试验以及这种罕见疾病的未来前景。
Salivary gland carcinomas (SGC) account for less than 5% of head and neck malignant neoplasms, further subcategorized in over 20 histological subtypes. For the most part, treatment for advanced disease is guided by morphology. SGC in general respond poorly to standard chemotherapy, with short durability and significant toxicity. More recently, next-generation sequencing provided significant input on the molecular characterization of each SGC subtype, not only improving diagnostic differentiation between morphologically similar tumor types, but also identifying novel driver pathways that determine tumor biology and may be amenable to targeted therapy. Amongst the most common histological subtype is adenoid cystic carcinoma, which often harbors a chromosome translocation resulting in a MYB-NFIB oncogene, with various degrees of Myb expression. In a smaller subset, NOTCH1 mutations occur, conferring a more aggressive disease and potential sensitivity to Notch inhibitors. Salivary duct carcinomas may overexpress Her-2 and androgen receptor, with promising clinical outcomes after exposure to targeted therapies approved for other indications. Secretory carcinoma, previously known as mammary analogue secretory carcinoma, is distinguished by an ETV6-NTRK3 fusion that can both help differentiate it from its morphologically similar acinar cell carcinoma and also make it susceptible to Trk inhibitors. In the present article, we discuss the molecular abnormalities, their impact on tumor biology, and therapeutic opportunities for the most common SGC subtypes and review published and ongoing clinical trials and future perspectives for this rare diseases.
登录
查看更多内容
影响因子：
6.4
作者：
Boon, Eline;Bel, Miranda;van Herpen, Carla M. L.
通讯作者：
van Herpen, Carla M. L.
DOI：
10.1200/jco.2016.67.5264
发表时间：
2017-01-20
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Ferrarotto R;Mitani Y;Diao L;Guijarro I;Wang J;Zweidler-McKay P;Bell D;William WN Jr;Glisson BS;Wick MJ;Kapoun AM;Patnaik A;Eckhardt G;Munster P;Faoro L;Dupont J;Lee JJ;Futreal A;El-Naggar AK;Heymach JV
通讯作者：
Heymach JV
影响因子：
1.2
作者：
Almeida LO;Guimarães DM;Martins MD;Martins MAT;Warner KA;Nör JE;Castilho RM;Squarize CH
通讯作者：
Squarize CH
影响因子：
45.3
作者：
Agulnik, Mark;Cohen, Ezra W. E.;Siu, Lillian L.
通讯作者：
Siu, Lillian L.
影响因子：
8
作者：
Chen, Z.;Chen, J.;Wu, L.
通讯作者：
Wu, L.